A multicenter, non-interventional, prospective study of the safety and efficacy of tocilizumab in the treatment of rheumatoid arthritis in the real world

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000032678

Enrollment

Unknown

Registered

2020-05-06

Start date

2020-06-10

Completion date

Unknown

Last updated

2020-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

case series:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patient aged >=18 years. 2. Patients diagnosed with RA according to the revised (2010) ACR criteria. 3. Patients are treated with tocilizumab according to the judgment of the treating doctor. 4. Sign written informed consent.

Exclusion criteria

Exclusion criteria: 1. The patient is receiving or has received any trial drug treatment within 4 weeks before enrollment in this study (or the 5 half-life periods of the trial drug, whichever is longer). 2. Subjects with contraindications in the study drug instructions (known to be allergic to the study drug or its excipients or have active infection).

Design outcomes

Primary

Measure	Time frame
DAS28;	—

Secondary

Measure	Time frame
CRP and ESR;Quality of life assessment;Adverse events;	—

Countries

China

Contacts

Public ContactYi Liu

yi2006liu@163.com+86 18980602061

Outcome results